How Babler was paid
$5.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Incentive | Total |
|---|---|---|---|---|
| Martin BablerPresident, Chief Executive Officer, and Chairman of the Board | $680,830 | $4,743,220 | $524,239 | $5,948,289 |
| David M. Goldstein, Ph.D.Chief Scientific Officer | $526,401 | $1,187,353 | $294,785 | $2,008,539 |
| Jörn Drappa, M.D., Ph.D.Chief Medical Officer | $523,755 | $1,161,607 | $293,303 | $1,978,665 |
What changed and why
- $5.9M$5,948,289 was CEO total compensation in 2025, down from $10,661,219 in 2024.
- $4.7M$4,743,220 of CEO compensation consisted of option awards, with no stock awards reported.
- 140%140% achievement of corporate goals determined the 2025 annual performance bonuses.
- 55%55% was Martin Babler’s target bonus opportunity as a percentage of base salary.
- 40%40% was the target bonus opportunity for David Goldstein and Jörn Drappa.
- Options and RSUs are the company’s primary long-term incentive vehicles.
Other Alumis proxy statements
- 2025 proxy statement
Martin Babler paid $10.7M (+132% on the year).
Filed Jun 16, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.